Chen Schor is President and CEO of Adicet Bio, a leader in the field of gamma-delta CAR T cell therapies for the treatment of cancer. With more than 25 years of global biopharmaceutical leadership experience, he has led several biotech companies across all stages, from formation, to early-stage discovery, to publicly traded multi-product companies with significant industry partnerships.
Mr. Schor has led strategic transactions valued at over $8 billion with companies such as GSK, Amgen, Pfizer, Merck KGaA and equity financing totaling more than $500 million. He led the turnaround of Synta Pharmaceuticals and its reverse merger with Madrigal Pharmaceuticals (Nasdaq: MDGL), served as Vice President, Global Branded Business Development and Pipeline Management at Teva Pharmaceuticals and in leadership positions at several emerging private and public companies. Mr. Schor was a Partner at Yozma Venture Capital where he led the foundation and growth of multiple therapeutic companies from inception to significant commercial success and exit.
He is a board member with the Alliance for Cancer Gene Therapy, a non-for-profit organization committed to advancing new cancer cell and gene therapies, Chairman of the Board of Carbon Biosciences, a gene therapy company, and board member with Karyopharm Therapeutics, a commercial stage oncology company.
Mr. Schor holds a MBA, a B.A. in Biology, a B.A. in Economics and is a Certified Public Accountant (CPA).
How old is Chen Schor BA?
Mr. BA is currently 52 years old. There are 5 older executives and no younger executives at Adicet Bio. The oldest executive at Adicet Bio is Dr. Aya Jakobovits Ph.D., Founder & Independent Director, who is 69 years old. Learn More on Chen Schor BA's age.
How do I contact Chen Schor BA?
Has Chen Schor BA been buying or selling shares of Adicet Bio?
Who are Adicet Bio's active insiders?
Are insiders buying or selling shares of Adicet Bio?
In the last twelve months, Adicet Bio insiders bought shares 1 times. They purchased a total of 3,125,000 shares worth more than $7,500,000.00. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 5,900 shares worth more than $8,437.00. The most recent insider tranaction occured on June, 5th when Director Michael Kauffman sold 5,900 shares worth more than $8,437.00. Insiders at Adicet Bio own 19.1% of the company.
Learn More about insider trades at Adicet Bio. Information on this page was last updated on 6/5/2024.
